Vyome Holdings, Inc. (NASDAQ:HIND) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $9.25.

A number of equities analysts have commented on the stock. Chardan Capital began coverage on shares of Vyome in a research note on Thursday, September 3rd. They set a “buy” rating and a $3.50 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th.

Vyome Stock Down 3.0%

HIND opened at $1.95 on Thursday. The company has a market cap of $13.69 million, a price-to-earnings ratio of -0.58 and a beta of 1.50. Vyome has a 52-week low of $1.75 and a 52-week high of $9.56. The firm’s fifty day simple moving average is $2.16 and its two-hundred day simple moving average is $2.22.

Vyome (NASDAQ:HIND) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.27 million during the quarter. Vyome had a negative net margin of 3,024.84% and a negative return on equity of 197.33%.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.